|Bid||220.05 x 1100|
|Ask||222.30 x 900|
|Day's range||218.38 - 224.91|
|52-week range||214.88 - 468.55|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||21.76|
|Earnings date||03 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||284.20|
The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.
Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day.
Over the past year, shares of Biogen (NASDAQ: BIIB) have dropped by 13.25% while the S&P 500 has climbed by 23.74%. The biotech's poor performance might come as a bit of a surprise since last year its Alzheimer's disease (AD) drug Aduhelm became the first medicine approved in the U.S. for the illness since 2003. Do the company's recent woes represent a buying opportunity or should investors stay away?